Digital PCR Microsatellite Mutation Detection for Low-DNA MSI Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting microsatellite instability (MSI) in tumors, such as PCR-based assays and next-generation sequencing, have limitations in sensitivity, requiring a minimum tumor cellularity of 20% and are not effective for analyzing low-concentration DNA samples, particularly from liquid biopsies.
Innovation Solution
A digital PCR method using droplet digital PCR (ddPCR) with two hydrolysis probes, one targeting the microsatellite sequence (MS probe) and another targeting a non-variable region (REF probe), allows for sensitive detection of MSI by analyzing fluorescence signals in individual droplets, achieving a detection limit 250 times lower than traditional methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional PCR-based assays or next-generation sequencing are used for MSI detection, then the detection method is established and can be performed with standard equipment, but the sensitivity is limited and requires a minimum tumor cellularity of 20%
Solution Approach 1:
The patent applies segmentation by dividing the DNA sample into numerous individual droplets (thousands to millions of partitions), where each droplet contains at most one target DNA molecule. This digital partitioning enables detection of rare mutant alleles among wild-type alleles by counting positive droplets, achieving sensitivity down to 0.1% mutant allele frequency, far exceeding traditional PCR and NGS methods that require 20% tumor cellularity.
Solution Approach 2:
The patent uses fluorescently labeled hydrolysis probes as intermediaries to detect microsatellite instability. These probes specifically bind to microsatellite regions and emit fluorescence signals that indicate the presence of mutant alleles. The probe-based detection system serves as an intermediary mechanism that translates molecular changes into measurable optical signals, enabling highly sensitive detection without requiring complex sequencing equipment.
2Measurement precision
If traditional PCR-based assays are used for MSI detection, then the method is simpler and uses standard equipment, but the analysis time is longer and the sensitivity remains above 1% even with NGS improvements
Solution Approach 1:
The patent performs preliminary amplification of target DNA regions before digital partitioning and detection. This pre-amplification step ensures sufficient target material is available for distribution into droplets, enabling sensitive detection of low-abundance mutant alleles. The preliminary action of amplification followed by digital partitioning allows the method to achieve 0.1% sensitivity while maintaining relatively fast analysis time compared to traditional sequential methods.
Solution Approach 2:
The patent replaces the mechanical separation and size analysis systems (capillary electrophoresis) with a digital counting system based on fluorescent detection. Instead of physically separating and measuring DNA fragment sizes through electrophoresis, the system uses fluorescent probes and digital droplet counting to detect microsatellite instability, significantly reducing analysis time while improving sensitivity to 0.1%.
3Reliability
If digital droplet PCR with two hydrolysis probes is used, then the detection sensitivity reaches 0.1% and can analyze low-concentration DNA samples, but the device complexity and probe design requirements increase
Solution Approach 1:
The patent applies local quality by designing hydrolysis probes with specific properties tailored for microsatellite detection. The probes are engineered with fluorescent labels and quenchers positioned at specific locations to optimize signal generation upon hybridization to microsatellite regions. This localized optimization of probe structure and fluorescence properties enables reliable detection of mutant alleles at 0.1% frequency while managing the complexity through targeted design rather than system-wide complexity.
Solution Approach 2:
The patent changes key detection parameters by using digital droplet partitioning combined with fluorescent signal thresholding. Instead of relying on continuous signal intensity measurements, the system counts discrete positive droplets, changing the detection parameter from analog to digital. This parameter change enables reliable detection at 0.1% sensitivity by statistical counting, overcoming the reliability limitations of traditional continuous measurement methods even with increased probe system complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides highly specific and sensitive MSI detection down to 0.1% sensitivity, enabling accurate diagnosis and monitoring of MSI in various cancers using liquid biopsies with improved simplicity and reduced analysis time.
Implementation Method 1
two hydrolysis probes, one targeting the microsatellite sequence (MS probe) and another targeting a non-variable region (REF probe), allows for sensitive detection of MSI by analyzing fluorescence signals in individual droplets
Data Source
Figure 1A~1C
Figure 1D~1F
Figure 1G~1I
AI summary
The present invention relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising a step of subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: - a pair of primers suitable for amplifying said target fragment of the DNA sample including said microsatellite sequence; - a first MS oligonucleotide (MS) hydrolysis probe, labeled with a first fluorophore, wherein said first MS oligonucleotide probe is complementary to a wild-type sequence including the microsatellite sequence; - a second oligonucleotide reference (REF) hydrolysis probe, labeled with a second fluorophore, wherein said second oligonucleotide REF probe is complementary to a wild-type sequence of said target DNA fragment which does not include said microsatellite sequence. The present invention also encompasses methods for the diagnosis and prognosis of cancer and a method for determining the efficacy of a cancer treatment. The invention also includes a kit for detecting a mutation in a microsatellite sequence.